Prostamax

Prostamax (KEDP, Lys-Glu-Asp-Pro) is a synthetic tetrapeptide from the Khavinson short-peptide bioregulator family — the same structural class as Epitalon (AEDG), Livagen (KED), and Pinealon (EDR). Unlike receptor-binding peptides such as BPC-157 or the GHRPs, the Khavinson peptides act at the chromatin level: they slip into DNA and reorganise how prostate and lymphoid tissue reads its own genome. The practical outcome the community cares about — quieter inflammation in prostatic tissue, preserved urinary and sexual function, and a maintenance-grade longevity effect — flows downstream of that epigenetic mechanism.

Sequence-Specific DNA and Histone Interaction#

The defining feature of the Khavinson peptides is that they don't bind a membrane receptor. They cross the cell membrane, enter the nucleus, and interact directly with double-stranded DNA in the major groove at tissue-specific promoter regions, and with histones H1, H2B, H3 and H4. KEDP's lysine and glutamate/aspartate side chains give it affinity for specific base-pair sequences concentrated in prostate-expressed genes, which is the structural basis for the peptide's tissue selectivity.

"The action of short synthetic peptides is based not on receptor binding but on sequence-specific interaction with nucleic acids and histones, leading to a persistent activation of chromatin." — Khavinson VKh, Lezhava TA, Malinin VV, Bulletin of Experimental Biology and Medicine, 2004

Practically, this is why the plasma half-life (minutes) is decoupled from the biological effect (weeks). The peptide is long gone by the time transcriptional output has shifted — which is also why dosing is pulsed (10–20 consecutive days, 1–2× per year) rather than chronic.

Heterochromatin Decondensation in Aged Cells#

Aged cells accumulate condensed, transcriptionally silent heterochromatin — genes that used to be active get packed away and shut off. KEDP reverses this phenotype in a measurable, cytogenetic way. In lymphocytes from donors aged 75–88, KEDP exposure reopened pericentromeric and telomeric heterochromatin, increased sister-chromatid exchanges in telomeric regions, and brought silenced euchromatic genes back online.

"The Lys-Glu-Asp-Pro peptide caused deheterochromatinization of pericentromeric and telomeric heterochromatin in lymphocytes from elderly donors, with increased sister-chromatid exchanges and activation of previously silenced genes." — Dzhokhadze TA et al., Georgian Medical News, 2012

For the longevity-focused user this is the mechanistic hook: the peptide doesn't stimulate, it un-silences. It restores a transcriptional capacity that ageing took away. The same paper documented increased active nucleolus organiser regions (NORs) — meaning rRNA genes came back online and protein-synthesis capacity was partially restored in senescent cells.

Restoration of Tissue-Specific Gene Expression#

Once chromatin opens at the right promoters, the relevant tissue gets back a transcriptional profile closer to its younger self. Across the Khavinson class this has been framed as a general mechanism for tissue-specific regeneration and anti-ageing effects.

"Khavinson short peptides modulate gene expression through direct chromatin interactions, contributing to the stimulation of tissue regeneration and anti-ageing effects." — Sinjari B, Diomede F, Khavinson V et al., Stem Cell Reviews and Reports, 2020

For KEDP the target tissue is prostatic epithelium. The practical downstream is better-regulated secretory function, reduced fibrotic/sclerotic drift in the stroma, and preserved acinar architecture — which is the mechanistic explanation for the anti-inflammatory data in the rat prostatitis model.

Prostate-Selective Anti-Inflammatory and Anti-Sclerotic Action#

The chromatin mechanism is elegant but abstract; the Borovskaya rat work is where it becomes physically concrete. In a ligature-induced chronic aseptic prostatitis model, KEDP outperformed both Serenoa repens (saw palmetto) and a prostate-extract reference on the histological readouts that matter — stromal oedema, vascular congestion, and lymphoid infiltration — and preserved copulative activity in treated animals.

"The use of Prostamax significantly reduced stromal edema, vascular hyperemia, and lymphoid infiltration in the chronic aseptic prostatitis model compared to control and reference groups." — Borovskaya TG et al., Modern Research in Inflammation, 2013

This is the mechanism AAS-experienced users are actually buying. High-DHT cycles (trenbolone, masteron, proviron, high-dose test) push prostatic tissue toward hypertrophy, elevated PSA, and flow changes. Prostamax doesn't block DHT — finasteride/dutasteride do that — it works on the other side of the problem, restoring the transcriptional and anti-inflammatory tone of the tissue that's under androgenic load.

Why the Effect Persists After Dosing Stops#

Epigenetic changes aren't pharmacokinetic events. Once chromatin has been decondensed at a given locus and the transcriptional machinery is reassembled, that state is maintained by the cell's own histone-modification and DNA-methylation enzymes for days to weeks after the peptide itself has been cleared.

"Short bioregulatory peptides interact with DNA and promote chromatin decondensation, leading to transcriptional activation of genes associated with tissue-specific restoration processes." — Khavinson VKh, Lezhava TA, Monaselidze JG et al., Bulletin of Experimental Biology and Medicine, 2002

This is the mechanistic justification for the Khavinson dosing model: a 10–20-day intensive pulse sets a new chromatin state, the body holds that state for months, and the course is repeated 1–2× per year rather than run continuously. Users who dose Prostamax daily for months on end aren't stacking benefit — they're ignoring how the compound actually works.

Common (most users)#

• Mild injection-site erythema or soreness. The most frequently reported effect. Rotate IM sites (glute, vastus lateralis, deltoid), warm the reconstituted solution to room temperature before injection, and use a fresh 29–31G pin per shot. If a site stays red >48 hours, move further from it on the next rotation.
• Transient mild headache in the first 2–4 days. Consistent with the chromatin-activation class (reported across Khavinson tetrapeptides). Hydration and holding the dose at 0.5 mg for the first three days before titrating to 1 mg is the usual mitigation.
• Transient fatigue or "heavy" feeling early in the course. Typically resolves by day 5–7. No dose reduction needed unless it persists; if it does, drop to 0.5 mg daily for the remainder of the pulse.

Uncommon (dose-dependent or individual)#

• Injection-site induration or small subcutaneous nodule. More common with SubQ than IM and more common at the upper end of the dose ladder (3–5 mg). Switch to IM, reduce volume by increasing reconstitution concentration, and the nodule typically resolves within 1–2 weeks.
• Transient PSA fluctuation during or immediately after a course. Modest shifts in total PSA can occur as prostatic tissue activity changes. This is why baseline PSA (total + free) is pulled before initiation and repeated ~8 weeks post-course — the trend matters, not a single in-course reading. A rising trend across two consecutive post-course draws is the signal to pause and get a urology workup, not to keep pulsing.
• Mild pelvic or perineal awareness. Reported occasionally in users with pre-existing prostatitis history during the first week of a course. Usually resolves by day 7–10. Persisting discomfort past two weeks warrants a urinalysis and culture to rule out a bacterial component the protocol is not designed to address.

"The use of Prostamax significantly reduced stromal edema, vascular hyperemia, and lymphoid infiltration in the chronic aseptic prostatitis model compared to control and reference groups." — Borovskaya et al., Modern Research in Inflammation (2013)

Rare but serious#

• Hypersensitivity / allergic reaction to the peptide or excipients. Urticaria, persistent localized swelling, or systemic symptoms (wheeze, facial swelling) warrant immediate discontinuation. Rare in the class but mechanistically possible with any parenteral peptide.
• Unexpected sustained rise in PSA across sequential post-course draws. Not a "side effect" of the peptide in the classical sense, but the clinically relevant signal that further use is inappropriate until imaging/biopsy clears the prostate. Stop the protocol, do not restart until cleared.
• Theoretical derepression concern. The mechanism is chromatin decondensation and activation of previously silenced genes in target tissues:

"The Lys-Glu-Asp-Pro peptide caused deheterochromatinization of pericentromeric and telomeric heterochromatin in lymphocytes from elderly donors, with increased sister-chromatid exchanges and activation of previously silenced genes." — Dzhokhadze et al., Georgian Medical News (2012)

No oncogenic signal has been reported in the available preclinical literature, but long-horizon human safety data outside Russian institutional practice do not exist. This is the rationale for keeping courses short (10–20 days), pulses infrequent (1–2× per year), and baseline/post-course PSA monitoring non-negotiable — not a reason to avoid the compound, but a reason to run it the way the Khavinson model actually specifies.

Hard contraindications#

• Active or suspected prostate cancer. The target tissue is the same tissue where malignancy would be growing. Do not use until cleared.
• Unexplained elevated PSA or an abnormal DRE that has not been worked up. Baseline PSA before initiation is not optional for this compound.
• Active bacterial prostatitis. The Borovskaya model is aseptic inflammation. Bacterial prostatitis requires antibiotic management first; the peptide is not a substitute.
• Known peptide hypersensitivity. Prior anaphylactoid reaction to any short peptide is a stop.
• Oral administration. Not a safety contraindication in the toxicity sense — it simply does not survive the gut. IM (preferred) or SubQ only.

Gender and PCT considerations#

Prostamax is a male-tissue-targeted peptide. All preclinical and community data are in males; there is no established rationale for female use and no reason to extrapolate one. There are no PCT considerations — the peptide does not bind androgen receptors, does not aromatize, does not suppress LH/FSH, and does not interact with the HPG axis. It can be run mid-cycle, during PCT, or between cycles without HPTA consequence. This makes it one of the few compounds where the "stack it whenever it fits the calendar" approach is genuinely fine — the only calendar that matters is the 10–20-day pulse length and the 6-month spacing between courses.